MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.21
+1.34
+13.58%
Closed 19:55 08/11 EDT
OPEN
9.90
PREV CLOSE
9.87
HIGH
11.25
LOW
9.77
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
29.40
52 WEEK LOW
4.920
MARKET CAP
1.93B
P/E (TTM)
-8.5874
1D
5D
1M
3M
1Y
5Y
--Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating
--Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating
MT Newswires · 23h ago
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.57% and 37.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
Recursion Pharmaceuticals Q2 EPS $(0.38) Down From $(0.31) YoY, Sales $7.67M Up From $2.55M YoY
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.38) per share. This is a 22.58 percent decrease over losses of $(0.31) per share from the same period last year. The company reported $7.67
Benzinga · 2d ago
Recursion Pharmaceuticals GAAP EPS of -$0.38, revenue of $7.67M
Recursion Pharmaceuticals press release (<span class...
Seekingalpha · 2d ago
-- Earnings Flash (RXRX) RECURSION Reports Q2 Revenue $7.7M
-- Earnings Flash (RXRX) RECURSION Reports Q2 Revenue $7.7M
MT Newswires · 2d ago
Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:
PR Newswire · 08/02 11:55
Cathie Wood’s Top 10 Buys in July
In this article, we discuss Cathie Wood’s top 10 buys in July. If you want to see more stocks that Cathie Wood bought this month, click Cathie Wood’s Top 5 Buys in July. In the beginning of July, Cathie Wood of ARK Investment Management admitted that while...
Insider Monkey · 07/28 19:40
Recursion Gains European Commission Orphan Drug Status For Rare Tumor Candidate
Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).
Benzinga · 07/21 14:00
More
No Data
Learn about the latest financial forecast of RXRX. Analyze the recent business situations of Recursion Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
20.00%Buy
80.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RXRX stock price target is 16.25 with a high estimate of 38.00 and a low estimate of 8.00.
High38.00
Average16.25
Low8.00
Current 11.21
EPS
Actual
Estimate
-0.30-0.19-0.090.02
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 131
Institutional Holdings: 97.69M
% Owned: 56.79%
Shares Outstanding: 172.01M
TypeInstitutionsShares
Increased
39
5.56M
New
22
1.53M
Decreased
37
4.64M
Sold Out
21
1.79M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Non-Executive Chairman/Independent Director
R. Martin Chavez
President/Chief Operating Officer
Tina Larson
Chief Executive Officer/Director
Christopher Gibson
Chief Financial Officer/Primary Contact
Michael Secora
Other
Shafique Virani
Independent Director
Zachary Bogue
Independent Director
Blake Borgeson
Independent Director
Terry - Ann Burrell
Independent Director
Zavain Dar
Independent Director
Robert Hershberg
Independent Director
Dean Li
No Data
No Data
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.

Webull offers kinds of Recursion Pharmaceuticals Inc stock information, including NASDAQ:RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.